



HIV and hepatitis B medications – Updated boxed warnings

- In April 2017, the FDA approved changes to the drug labels of several human immunodeficiency virus type 1 (HIV-1) and hepatitis B medications, to remove information related to lactic acidosis/severe hepatomegaly with steatosis from the boxed warnings.
 - These drugs include [Atripla](#)[®], [Descovy](#)[®], [Emtriva](#)[®], [Genvoya](#)[®], [Odefsey](#)[®], [Stribild](#)[®], [Vemlidy](#)[®], and [Viread](#)[®].
- Atripla, Descovy, Emtriva, Genvoya, Odefsey, and Stribild are approved for the treatment of HIV-1 infection.
- Vemlidy is approved to treat chronic hepatitis B virus infections in adults with compensated liver disease.
- Viread is approved for the treatment of HIV-1 infection and chronic hepatitis B infection.
- The updated boxed warnings for these medications include the risk for post-treatment acute exacerbation of hepatitis B.
- Atripla also includes a new warning regarding the risk for QTc prolongation.
- For other safety updates, please refer to the individual drug label.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.